CLINICOPATHOLOGICAL SIGNIFICANCE OF PLASMINOGEN ACTIVATOR INHIBITOR-1 GENE POLYMORPHISM IN BREAST CANCER PATIENTS FROM NORTH WEST OF IRAN

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  2016-06-10

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinicopathological significance of plasminogen activator inhibitor-1 gene polymorphism in breast cancer patients from North West of Iran

  2018cited by this paper
• The Effect of PAI-1 4G/5G Polymorphism and Clinical Factors on Coronary Artery Occlusion in Myocardial Infarction

  2015cited by this paper
• Functional Stability of Plasminogen Activator Inhibitor-1

  2014cited by this paper
• Association of Plasminogen Activator Inhibitor-1 Gene Polymorphism with Inflammatory Bowel Disease in Iranian Azeri Turkish Patients

  2014cited by this paper
• PAI-1 4G/5G Polymorphism Contributes to Cancer Susceptibility: Evidence from Meta-Analysis

  2013cited by this paper
• Germ-line MTHFR C 677 T , FV H 1299 R and PAI-1 5 G / 4 G Variations in Breast Carcinoma

  2013cited by this paper
• Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.

  2013cited by this paper
• Germ-line MTHFR C677T, FV H1299R and PAI-1 5G/4G variations in breast carcinoma.

  2013cited by this paper
• PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis

  2012cited by this paper
• Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer.

  2009cited by this paper
• PAI-1 −675 4G/5G polymorphism as a prognostic biomarker in breast cancer

  2008cited by this paper
• Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast.

  2008cited by this paper
• Functional Plasminogen Activator Inhibitor-1 Gene Variants and Breast Cancer Survival

  2006cited by this paper
• Prognostic Value of PAI1 in Invasive Breast Cancer: Evidence That Tumor-Specific Factors Are More Important Than Genetic Variation in Regulating PAI1 Expression

  2006cited by this paper
• Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.

  2006cited by this paper
• Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.

  2006cited by this paper
• Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.

  2000cited by this paper

• مَس ، دادرخ 9315 Clinicopathological significance of plasminogen activator inhibitor-1 gene polymorphism in breast cancer patients from

  2018cites this paper
• Clinicopathological significance of plasminogen activator inhibitor-1 gene polymorphism in breast cancer patients from North West of Iran

  2018cites this paper
• THE ASSOCIATION OF 4G/5G POLYMORPHISM OF PAI-1-675 GENE WITH CLINICOPATHOLOGIC FEATURES OF THYROID TUMORS IN IRANIAN AZERI TURKISH PATIENTS

  2017influential citation
• Clinicopathological significance of plasminogen activator inhibitor-1 gene polymorphism in breast cancer patients from North West of Iran

  2016cites this paper